68-1

18/98

19) Michelson D, Snyder E, Paradis E, et al: Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontin-uation: a phase 3 randomised, double-blind, place-bo-controlled trial. Lancet Neurol, 2014; 13: 461-471.20) Ma J, Svetnik V, Snyder E, Lines C, Roth T, Herring WJ: Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects. Sleep, 2014; 37: 1609-1619.21) Winrow CJ, Gotter AL, Cox CD, et al: Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist. J Neurogenet, 2011; 25: 52-61.22) BELSOMRAⓇ package insert. http://www.info.pmda.go.jp/downfiles/ph/PDF/170050_1190023F1024_1_06.pdf23) Yao L, Ramirez AD, Roecker AJ, et al: The dual orexin receptor antagonist, DORA-22, lowers histamine levels 16in the lateral hypothalamus and prefrontal cortex without lowering hippocampal acetylcholine. J Neuro-chem, 2017; 142: 204-214.24) Hatta K, Kishi Y, Wada K, et al: Preventive Effects of Suvorexant on Delirium: A Randomized Placebo-Con-trolled Trial. J Clin Psychiatry, 2017; 78: e970-e979.25) Azuma K, Takaesu Y, Soeda H, et al: Ability of suvorexant to prevent delirium in patients in the intensive care unit: a randomized controlled trial. Acute Med Surg, 2018; 5: 362-368.26) Xu S, Cui Y, Shen J, Wang P: Suvorexant for the preven-tion of delirium: a meta-analysis. Medicine, 2020; 99: 30(e21043).27) Hatta K, Kishi Y, Wada K, et al: Real-world effective-ness of ramelteon and suvorexant on delirium preven-tion in 967 patients with delirium risk factors. J Clin Psychiatry, 2020; 81: 19m12865.